Patents by Inventor Jincong Zhuo

Jincong Zhuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF
    Publication number: 20240140954
    Abstract: The disclosure relates to tricyclic heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
    Type: Application
    Filed: October 31, 2023
    Publication date: May 2, 2024
    Inventors: Jincong Zhuo, Yao Zhang, Zhangqi Yu, Dan Yan, Wenlai Zhou
  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20240124463
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: January 9, 2023
    Publication date: April 18, 2024
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11939340
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: March 26, 2024
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Jincong Zhuo, Xiaowei Wu, Katarina Rohlfing, Andrew Combs
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11905275
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: February 20, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20240018136
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: March 8, 2023
    Publication date: January 18, 2024
    Inventors: Jincong Zhuo, Andrew Combs
  • SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
    Publication number: 20230357275
    Abstract: The disclosure is directed to crystalline forms of the compound of Formula I: Formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: May 13, 2021
    Publication date: November 9, 2023
    Inventors: Jincong Zhuo, Ganfeng Cao, Andrew Paul Combs, Qun Li, Huaping Zhang
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20230257394
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: February 2, 2023
    Publication date: August 17, 2023
    Inventors: Jincong ZHUO, Xiaowei Wu, Katarina Rohlfing, Andrew Combs
  • CDK Inhibitors And Their Use As Pharmaceuticals
    Publication number: 20230234964
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 27, 2023
    Inventors: Jincong Zhuo, Xiaowei Wu, Katarina Rohlfing, Andrew Combs
  • SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
    Publication number: 20230212191
    Abstract: The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I) as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 6, 2023
    Applicant: PRELUDE THERAPEUTICS, INCORPORATED
    Inventors: Jincong ZHUO, Andrew Paul COMBS
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11685744
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: June 27, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Andrew W. Buesking, Andrew Paul Combs, Jincong Zhuo, Ryan Holmes, Sarah Pawley, Xiaowei Wu
  • BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20230159501
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: January 24, 2023
    Publication date: May 25, 2023
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • BCL-2 inhibitors and their use as pharmaceuticals
    Patent number: 11622970
    Abstract: The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: April 11, 2023
    Assignee: Prelude Therapeutics Incorporation
    Inventors: Jincong Zhuo, Andrew Paul Combs, Peng Wei, Jialiang Wang
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11591318
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein
    Publication number: 20230010358
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 12, 2023
    Inventors: Jincong Zhuo, Raul Leal, Rupa Shetty, Juan Luengo, Andrew Paul Combs, Peng Wei
  • Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors
    Publication number: 20230002392
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: January 13, 2022
    Publication date: January 5, 2023
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20220064170
    Abstract: The disclosure is directed to compounds of Formula I. Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: December 13, 2019
    Publication date: March 3, 2022
    Inventor: Jincong ZHUO
  • Imidazotriaines and imidazopyrimidines as kinase inhibitors
    Patent number: 11261191
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: March 1, 2022
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
    Patent number: 11229631
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: January 25, 2022
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
  • Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
    Patent number: 11214573
    Abstract: The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: January 4, 2022
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, David M. Burns, Jincong Zhuo
  • BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20210395246
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: January 28, 2021
    Publication date: December 23, 2021
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang